``Investing in Biotech: Profits and Pitfalls'' Is an Introduction to the World of Investing in Biotechnology.DUBLIN Dublin, city, Republic of Ireland Dublin, Irish Baile Átha Cliath, county borough (1991 pop. 915,516), Leinster, capital of the Republic of Ireland, on Dublin Bay at the mouth of the Liffey River. , Ireland Ireland, Irish Eire (âr`ə) [to it are related the poetic Erin and perhaps the Latin Hibernia], island, 32,598 sq mi (84,429 sq km), second largest of the British Isles. -- Research and Markets (http://www.researchandmarkets.com/reports/c31313) has announced the addition of Investing in Biotech bi·o·tech n. Informal Biotechnology. biotech Noun short for biotechnology Noun 1. : Profits and Pitfalls to their offering. This report provides the information necessary to profit from the unfolding technological and scientific advances in biotechnology biotechnology, the use of biological processes, as through the exploitation and manipulation of living organisms or biological systems, in the development or manufacture of a product or in the technological solution to a problem. . It offers specific tips on how to get started, where to find the information needed to identify and analyze an·a·lyze v. 1. To examine methodically by separating into parts and studying their interrelations. 2. To separate a chemical substance into its constituent elements to determine their nature or proportions. 3. specific investment opportunities, and how to time investments around company events and valuation inflection points Inflection Point An event that changes the way we think and act. -Andy Grove, Founder of Intel. Notes: For example, the fall of the Berlin Wall was an inflection point in global politics and the commercialization of the Internet was an inflection point in technology. . Reasons to Purchase --Understand the market dynamics and regulatory reg·u·late tr.v. reg·u·lat·ed, reg·u·lat·ing, reg·u·lates 1. To control or direct according to rule, principle, or law. 2. events driving biotechnology company valuations --Identify the emerging technologies most likely to yield significant new drugs --Recognize potential investment opportunities in biotechnology --Identify 26 companies, five mutual funds and three ETFs for potential investment Target Audience --Fund managers, venture capitalists Venture Capitalist An investor who provides capital to either start-up ventures or support small companies who wish to expand but do not have access to public funding. Notes: Venture capitalists usually expect higher returns for the additional risks taken. and individual investors seeking investments in biotech --Analysts and journalists tracking the biotechnology market --Others seeking to understand the driving factors and market dynamics Report Highlights "Investing in Biotech: Profits and Pitfalls" is an introduction to the world of investing in biotechnology. While there are many opportunities to profit from the unfolding technological and scientific advances, biotechnology is a complex, high beta industry. As such, investors should be armed with some basic knowledge and principles to maximize In a graphical environment, to enlarge a window to the full size of the screen. See Win Maximize windows. their returns in biotech. One of the added benefits of investing in biotech is "to do good while doing well." You are contributing to the success of companies that are striving to extend patients' lives and find cures for deadly diseases such as cancer. New advances are made nearly daily, and by investing in biotech you are contributing to that progress while hopefully pocketing some profits. The report provides a wealth of information on how clinical trials and other events effect company valuation, the emerging technologies shaping the future of biotech, and the performance of biotechs over pharmaceutical companies. In addition to the 26 companies covered in the report, it also discusses EFTs and mutual funds as potential investment opportunities. "Investing in Biotech: Profits and Pitfalls" is a valuable source of information for the new investor in biotech as well as the seasoned investor seeking additional insights into the market dynamics. Companies Mentioned: Aastrom Abgenix Advance Cell Technology Amgen Biogen Idec Cambridge Antibody Technology Corautus Curis Exelixis Genentech GenVec Genzyme Geron Gilead GlaxoSmithKline Hybridon ImClone Invitrogen Johnson & Johnson Lexicon Genetics New River Pharma Pfizer Shire Pharmaceuticals StemCells Vertex ViaCell For more information visit http://www.researchandmarkets.com/reports/c31313 |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion